Zacks.com on MSN2d
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals
The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal ...
Zacks.com on MSN2d
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)
The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal ...
FierceBiotech3d
GSK's depemokimab reduces polyps in phase 3 trials, adding weight to upcoming filing
GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been ...
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year
GSK's depemokimab met key endpoints in phase 3 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), showing promise ...
pharmaphorum3d
GSK asthma hope depemokimab works in second indication
Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 ...
The Pharma Letter3d
GSK’s depemokimab scores well in CRSwNP trials
UK pharma major GSK today announced positive headline results from two Phase III clinical trials, ANCHOR-1 and ANCHOR-2, ...
Daily4d
Twice-Yearly Depemokimab Effectively Lowers Exacerbation Rates in Severe Eosinophilic Asthma: Study Reveals
The findings reveal that administering Depemokimab twice yearly significantly lowers the annualized rate of asthma ...
GSK reports positive results from depemokimab trial
GSK has announced positive results from a phase III trial of its depemokimab treatment for chronic rhinosinusitis with nasal ...